Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin and Temozolomide in Newly Diagnosed GBM
NCT00590681Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Feb 2007
- Primary completion
- Sep 2014
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in glioblastoma multiforme (GBM), sponsored by University of Chicago. Primary endpoint: Objective Response at 3 years. Started Feb 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00590681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00590681.